HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Acotec Scientific Holdings - First-Mover Advantage Together with Challenges

Pre-IPO Shanghai HeartCare Medical Technology - Promising Market but Fierce Competition

Pre-IPO Kindstar Globalgene Technology - A New Start with More Challenges

Pre-IPO Chaoju Eye Care Holdings - Here Are the Strength and the Concerns

New Horizon Health (6606.HK) - Still Has a Long Way to Go

Pre-IPO Angelalign Technology - Promising Market but Full of Challenges

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Capital Markets

Zhaoke Ophthalmology Pharmaceutical / Equity Capital Markets

Zhaoke Ophthalmology Pharmaceutical (6622 HK)

<p>On December 18<sup>th</sup> 2020, <a href="https://www.smartkarma.com/entities/lee-s-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:14616:1" rel="noopener">Lee's Pharmaceutical (950 HK)</a> announced that it had submitted an application to the Hong Kong Stock Exchange for approval to list <a href="https://www.smartkarma.com/entities/zhaoke-ophthalmology-pharmaceutical" target="_blank" data-smartkarma-citation="entities:31495:1" rel="noopener">Zhaoke Ophthalmology Pharmaceutical (ZKO HK)</a> on the main board of the HKEX. It is worth mentioning that, before the IPO, Lee's Pharmaceuticals holds 34.1% shares in Zhaoke, and Zhaoke is the affiliated company of the group. After the spin-off and listing, Lee's Pharmaceuticals would no longer be Zhaoke's controlling shareholder, but would still be its single largest shareholder. Meanwhile, at present, there are some good listed companies in the ophthalmology industry in the secondary capital market, such as <a href="https://www.smartkarma.com/entities/chengdu-kanghong-pharmaceu-a" target="_blank" data-smartkarma-citation="entities:24723:1" rel="noopener">Chengdu Kanghong Pharmaceu-A (002773 CH)</a> and <a href="https://www.smartkarma.com/entities/shenyang-xingqi-pharmaceut-a" target="_blank" data-smartkarma-citation="entities:29617:1" rel="noopener">Shenyang Xingqi Pharmaceut-A (300573 CH)</a>. As a "new force", how would Zhaoke perform compared with its strong peers in this industry?</p>

On December 18th 2020, Lee's Pharmaceutical (950 HK) announced that it had submitted an application to the Hong Kong Stock Exchange for approval to list Zhaoke Ophthalmology Pharmaceutical (ZKO HK) on the main board of the HKEX. It is worth mentioning that, before the IPO, Lee's Pharmaceuticals holds 34.1% shares in Zhaoke, and Zhaoke is the affiliated company of the group. After the spin-off and listing, Lee's Pharmaceuticals would no longer be Zhaoke's controlling shareholder, but would still be its single largest shareholder. Meanwhile, at present, there are some good listed companies in the ophthalmology industry in the secondary capital market, such as Chengdu Kanghong Pharmaceu-A (002773 CH) and Shenyang Xingqi Pharmaceut-A (300573 CH). As a "new force", how would Zhaoke perform compared with its strong peers in this industry?

Shandong Sinobioway Biomedicine (002581 CH)

Chengdu Kanghong Pharmaceutical Group-A (002773 CH)

Shenyang Xingqi Pharmaceutical (300573 CH)

Pre-IPO Zhaoke Ophthalmology Pharmaceutical - It Remains to Be Seen How to Find Its Way Out